A study testing whether a GLP-1 medicine, semaglutide, can help people with spinal cord injuries lower blood sugar.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Male and female subjects aged 18-70 years (inclusive) at screening
• More than one year after spinal cord injury
• Levels if injury C2-L2 with Asia Impairment Scale A, B, C or D.
• Provision of signed and dated written informed consent prior to any study specific procedures
• Diagnosed with T2DM with glucose control managed with diet and metformin monotherapy where no significant dose changes (increase or decrease ≥ 50%) have occurred in the three months prior to screening

Key exclusion criteria

• History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures.
• Any subject who has received another investigational product as part of a clinical study within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening
• Taking mirabegron or other glucose altering medications
• Taking steroids within the past 1 year
• Significant anemia (hemoglobin\<11g/dL)